Oric Pharmaceuticals, Inc. $ORIC Stake Raised by Royce & Associates LP

Royce & Associates LP raised its holdings in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 521.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,458,483 shares of the company’s stock after acquiring an additional 1,223,709 shares during the quarter. Royce & Associates LP owned 1.50% of Oric Pharmaceuticals worth $17,502,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in ORIC. Vanguard Group Inc. raised its holdings in shares of Oric Pharmaceuticals by 48.8% in the 3rd quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock worth $55,802,000 after purchasing an additional 1,525,445 shares in the last quarter. JPMorgan Chase & Co. grew its position in Oric Pharmaceuticals by 3,646.1% in the second quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after buying an additional 1,299,799 shares during the last quarter. Vivo Capital LLC grew its position in Oric Pharmaceuticals by 50.3% in the second quarter. Vivo Capital LLC now owns 3,126,604 shares of the company’s stock worth $31,735,000 after buying an additional 1,046,154 shares during the last quarter. Eventide Asset Management LLC bought a new position in shares of Oric Pharmaceuticals in the second quarter valued at $9,657,000. Finally, Alkeon Capital Management LLC lifted its position in shares of Oric Pharmaceuticals by 12.5% during the 2nd quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock valued at $45,717,000 after acquiring an additional 500,000 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ORIC shares. JPMorgan Chase & Co. lifted their target price on Oric Pharmaceuticals from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Wells Fargo & Company increased their price target on Oric Pharmaceuticals from $19.00 to $25.00 and gave the company an “overweight” rating in a research report on Monday, December 8th. Wolfe Research initiated coverage on Oric Pharmaceuticals in a report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Wall Street Zen raised shares of Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.20.

Oric Pharmaceuticals Price Performance

Shares of ORIC opened at $13.88 on Tuesday. The business’s 50-day moving average is $10.50 and its 200-day moving average is $11.05. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -9.13 and a beta of 1.35. Oric Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04. Equities research analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Insider Buying and Selling at Oric Pharmaceuticals

In other news, insider Pratik S. Multani sold 10,720 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20. Following the transaction, the insider directly owned 68,149 shares in the company, valued at $617,429.94. The trade was a 13.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Dominic Piscitelli sold 52,000 shares of the company’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total transaction of $702,520.00. Following the completion of the transaction, the chief financial officer directly owned 68,148 shares in the company, valued at $920,679.48. This trade represents a 43.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 106,814 shares of company stock valued at $1,199,135 in the last quarter. Company insiders own 6.82% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.